STAT

Opinion: Medicare Part B needs reform, but Trump’s proposal faces insurmountable challenges

Medicare Part B needs reform, but I worry that Trump's plan will meet the same ruinous fate as prior proposals.
President Trump announces a plan to overhaul how Medicare pays for certain drugs during a speech Thursday at the Department of Health and Human Services in Washington.

President Trump’s timely speech Thursday about high drug prices addressed key problems that make drugs unaffordable for so many Americans, and for taxpayers in general. With less than two weeks until the midterm elections, and drug prices a key issue for voters, the speech sent a message that the administration recognizes voters’ concerns, and is doing something about them.

Although the effort put into addressing drug pricing by the Trump administration is impressive, the solutions proposed Thursday face insurmountable challenges. I worry that the plan will meet the same (ruinous) fate as prior proposals

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks